Sells blood and tissue tests for cancer treatment selection, disease monitoring and colorectal cancer screening to physicians, hospitals and cancer centers. Also provides tests and data services to biopharmaceutical companies.
10-K for FY2025, filed Feb 19, 2026We are a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. We are…View ↗
We also collaborate with biopharmaceutical companies in clinical studies by providing the above-mentioned tests, as well as the…View ↗
For early cancer detection, we offer the Shield blood test for colorectal cancer screening in adults age 45 and older who are at average…View ↗
Oncology revenue was previously presented as precision oncology revenue from tests for clinical customers. Oncology revenue includes…View ↗
We believe our Guardant360 CDx test was the first comprehensive liquid biopsy test approved by the FDA, and is the market leading…View ↗
For oncology tests, the company earns revenue when results are reported to physicians, with patients, commercial and government payers, hospitals and cancer centers among those paying. Biopharma customers pay per test or for testing and related services over time or at milestones; the company also earns revenue by licensing technology.
10-K for FY2025, filed Feb 19, 2026The Company derives revenue from four major sources, including oncology, biopharma and data, screening, and licensing and other. The…View ↗
Oncology revenue was previously presented as precision oncology revenue from tests for clinical customers. Oncology revenue includes…View ↗
Oncology revenue is recognized at the time results of the test are reported to physicians. Most oncology tests requested by clinical…View ↗
Revenue from the delivery of the Company's tests for biopharmaceutical customers are based on a negotiated price per test or on the basis…View ↗
In addition, the Company collaborates with biopharmaceutical companies in the development of new drugs. As part of these collaborations…View ↗
10-K for FY2025, filed Feb 19, 2026
FY2025 revenue by product or service ↗$982M
10-K for FY2025, filed Feb 19, 2026
$982M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Oncology
Sold outright
10-K for FY2025, filed Feb 19, 2026 |
70% |
Oncology, FY2025
$683.6M Sources
|
Sold outright |
|
Biopharma and data
Mix
10-K for FY2025, filed Feb 19, 2026 |
21% |
Biopharma and data, FY2025
$210.1M Sources
|
Mix |
|
Screening
Sold outright
|
8.1% |
Screening, FY2025
$79.7M Sources
|
Sold outright |
|
Licensing and other
Licensed
|
0.9% |
Licensing and other, FY2025
$8.6M Sources
|
Licensed |
Hospitals, cancer centers, research institutions and patients are clinical customers; tests are also delivered through laboratories operated by strategic partners. Biopharma companies buy tests and development, data and referral services, while international laboratory partners and distributors are also customers.
10-K for FY2025, filed Feb 19, 2026The Company derives revenue from four major sources, including oncology, biopharma and data, screening, and licensing and other. The…View ↗
Oncology revenue was previously presented as precision oncology revenue from tests for clinical customers. Oncology revenue includes…View ↗
Biopharma and data revenue includes amounts derived from the delivery of the Company's tests for biopharmaceutical customers, previously…View ↗
No. It lost $416.3M in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$124.4MView ↗
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
Growing. Revenue grew 2.6x in 4 years, from $373.7M in FY2021 to $982M in FY2025, about 27% a year.
Shield screening status
The older report described Shield as a laboratory-developed test and planned an FDA submission; the latest describes it as FDA-approved for primary colorectal cancer screening and meeting Medicare coverage requirements.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 19, 2026According to American Cancer Society: Colorectal Cancer Facts & Figures 2020-2022, it is estimated that only 66% of adults at 50 years and…View ↗
In order to systematically address this need, we offer the Shield blood test to address the needs of individuals eligible for colorectal…View ↗
Competes with Foundation Medicine, Caris Life Sciences, Tempus AI, NeoGenomics, Exact Sciences, BillionToOne, Quest Diagnostics, Laboratory Corporation of America, Natera, Myriad Genetics, Personalis, GRAIL, Freenome Holdings, Delfi Diagnostics, Illumina, Thermo Fisher Scientific, Pacific Biosciences of California, Ultima Genomics, and Oxford Nanopore Technologies
10-K for FY2025, filed Feb 19, 2026Our competitors within the liquid biopsy space for therapy selection include Foundation Medicine, Inc., which was acquired by Roche…View ↗
Loading...